New Page 1

Print this page

Authors & contributors
Contents
Foreword
The COPD-X guidelines
Levels of evidence
Summary of the COPD-X guidelines
	Confirm diagnosis & assess severity
	Optimise function
	Prevent deterioration
	Develop support network
	Manage eXacerbations
Appendices
	Appendix 1
	Appendix 2
	Appendix 3
	Appendix 4
References
References reviewed but not cited

Appendix 1

Box 17: Use and doses of long-term inhaled bronchodilator and glucocorticoids determined in response trials

Response	Drug	Dose (mcg)	Frequency	Delivery
Improved airway function Improved exercise capacity Reduced breathlessness Improved quality of life	beta-agonist
	Salbutamol	200mcg	4–6-hourly	MDI/spacer
	Terbutaline	500 mcg	6–8-hourly	DPI
	Salmeterol	50 mcg	12-hourly	MDI/DPI
	Formoterol	12 mcg	12-hourly	MDI/DPI
	Anticholinergic
	Ipratropium	40-80 mcg	6–8-hourly	MDI/spacer
	Tiotropium	18 mcg	24-hourly	DPI
	Glucocorticoid			Inhaled
	Beclomethasone (small particle)	400-800 mcg/day	-	MDI/spacer
	Budesonide	800-1600 mcg/day	-	DPI
	Fluticasone	500-1000 mcg/day	-	MDI/DPI
	Ciclesonide	80-320mcg/day		MDI – spacer not recommended
	MDI = metered dose inhaler. DPI = dry powder inhaler.

Content last updated:

November 11, 2008

Page last updated:

November 12, 2008